Patents by Inventor Daniel Delorme

Daniel Delorme has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel compounds with analgesic effect
    Publication number: 20040171612
    Abstract: Compounds of general formula (I) 1
    Type: Application
    Filed: December 9, 2003
    Publication date: September 2, 2004
    Applicant: AstraZeneca Canada Inc.
    Inventors: Daniel Delorme, Edward Roberts, Zhongyong Wei
  • Compounds
    Patent number: 6777561
    Abstract: Compounds of general formula I are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: August 17, 2004
    Assignee: AstraZeneca Canada Inc.
    Inventors: Daniel Delorme, Vlad Gregor, Edward Roberts, Eric Sun
  • Inhibitors of histone deacetylase
    Publication number: 20040142953
    Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Application
    Filed: February 4, 2003
    Publication date: July 22, 2004
    Applicant: MethylGene, Inc.
    Inventors: Daniel Delorme, Zhihong Zhou
  • Inhibitors of histone deacetylase
    Publication number: 20040106599
    Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Application
    Filed: September 12, 2002
    Publication date: June 3, 2004
    Inventors: Daniel Delorme, Soon Hyung Woo, Arkadii Vaisburg, Oscar Moradei, Silvana Leit, Stephane Raeppel, Sylvie Frechette, Giliane Bouchain
  • Methods for specifically inhibiting histone deacetylase-7 and 8
    Publication number: 20040072770
    Abstract: This invention relates to the inhibition of histone deacetylase (HDAC) expression and enzymatic activity. The invention provides methods and reagents for inhibiting HDAC-7 and HDAC-8 by inhibiting expression at the nucleic acid level or inhibiting enzymatic activity at the protein level.
    Type: Application
    Filed: July 3, 2002
    Publication date: April 15, 2004
    Inventors: Jeffrey M. Besterman, Zuomei Li, Daniel Delorme, Claire Bonfils
  • Novel sulfonamidomethyl phosphonate inhibitors of beta-lactamase
    Publication number: 20040059115
    Abstract: The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel &bgr;-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic &bgr;-lactamase inhibitors presently available, and which do not require a &bgr;-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.
    Type: Application
    Filed: October 8, 2002
    Publication date: March 25, 2004
    Inventors: Jeffrey M. Besterman, Daniel Delorme, Jubrail Rahil
  • Compounds with analgesic effect
    Patent number: 6693117
    Abstract: Compounds of general formula (I) are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: February 17, 2004
    Assignee: AstraZeneca Canada Inc.
    Inventors: Daniel Delorme, Edward Roberts, Zhongyong Wei
  • Methods for inhibiting histone deacetylase-4
    Publication number: 20030152557
    Abstract: This invention relates to the inhibition of histone deacetylase (HDAC) expression and enzymatic activity. The invention provides methods and reagents for inhibiting HDAC-4 and HDAC-1 by inhibiting expression at the nucleic acid level or inhibiting enzymatic activity at the protein level.
    Type: Application
    Filed: January 14, 2002
    Publication date: August 14, 2003
    Inventors: Jeffrey M. Besterman, Claire Bonfils, Zuomei Li, Soon Hyung Woo, Arkadii Vaisburg, Daniel Delorme, Marielle Fournel, Rico Lavoie
  • Methods for specifically inhibiting histone deacetylase-4
    Publication number: 20030148970
    Abstract: This invention relates to the inhibition of histone deacetylase (HDAC) expression and enzymatic activity. The invention provides methods and reagents for inhibiting HDAC-4 and HDAC-1 by inhibiting expression at the nucleic acid level or inhibiting enzymatic activity at the protein level.
    Type: Application
    Filed: January 14, 2002
    Publication date: August 7, 2003
    Inventors: Jeffrey M. Besterman, Claire Bonfils, Zuomei Li, Soon Hyung Woo, Arkadii Vaisburg, Daniel Delorme, Marielle Fournel, Rico Lavoie
  • Novel compounds with analgesic effect
    Publication number: 20030149023
    Abstract: Compounds of general formula (I) 1
    Type: Application
    Filed: August 19, 2002
    Publication date: August 7, 2003
    Applicant: AstraZeneca Canada Inc.
    Inventors: Daniel Delorme, Edward Roberts, Zhongyong Wei
  • Inhibitors of histone deacetylase
    Patent number: 6541661
    Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: April 1, 2003
    Assignee: MethylGene, Inc.
    Inventors: Daniel Delorme, Rejean Ruel, Rico Lavoie, Carl Thibault, Elie Abou-Khalil
  • Sulfonamidomethyl phosphonate inhibitors of beta-lactamase
    Patent number: 6472406
    Abstract: The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel &bgr;-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic &bgr;-lactamase inhibitors presently available, and which do not require a &bgr;-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.
    Type: Grant
    Filed: July 5, 2000
    Date of Patent: October 29, 2002
    Assignee: MethylGene, Inc.
    Inventors: Jeffrey M. Besterman, Daniel Delorme, Jubrail Rahil
  • Compounds with analgesic effect
    Patent number: 6455545
    Abstract: Compounds of general formula (I) are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Grant
    Filed: January 18, 2001
    Date of Patent: September 24, 2002
    Assignee: AstraZeneca Canada Inc.
    Inventors: Daniel Delorme, Edward Roberts, Zhongyong Wei
  • Inhibitors of histone deacetylase
    Publication number: 20020115826
    Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Application
    Filed: March 26, 2001
    Publication date: August 22, 2002
    Inventors: Daniel Delorme, Soon Hyung Woo, Arkadii Vaisburg
  • Substituted urea compounds useful in pain management
    Patent number: 6387949
    Abstract: Compounds of general formula I are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: May 14, 2002
    Assignee: AstraZeneca Canada Inc.
    Inventors: Daniel Delorme, Vlad Gregor, Niklas Plobeck, Edward Roberts, Eric Sun
  • Compounds useful in pain management
    Patent number: 6376534
    Abstract: Compounds of general formula I are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain. Intermediates to the compounds of the formula I are also claimed.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: April 23, 2002
    Assignee: Astrazeneca Canada Inc.
    Inventors: Daniel Delorme, Vlad Gregor, Edward Roberts, Eric Sun
  • Novel compounds with analgesic effect
    Publication number: 20010021715
    Abstract: Compounds of general formula (I) 1
    Type: Application
    Filed: January 18, 2001
    Publication date: September 13, 2001
    Applicant: Astra Pharma Inc.
    Inventors: Daniel Delorme, Edward Roberts, Zhongyong Wei
  • Compounds with analgesic effect
    Patent number: 6187792
    Abstract: Compounds of general formula (I) are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Grant
    Filed: March 5, 1998
    Date of Patent: February 13, 2001
    Assignee: Astra Pharma Inc.
    Inventors: Daniel Delorme, Edward Roberts, Zhongyong Wei
  • Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
    Patent number: 5576338
    Abstract: Compounds having the Formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: February 15, 1995
    Date of Patent: November 19, 1996
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Richard Friesen, Yves Ducharme, Daniel Dube', Carole Lepine, Daniel Delorme, Pierre Hamel
  • Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis
    Patent number: 5552437
    Abstract: Compounds having the Formula I:R.sup.1 R.sup.2 C(OR.sup.3)--Ar.sup.1 --X--Ar.sup.2 --Ar.sup.3Ire inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: October 27, 1994
    Date of Patent: September 3, 1996
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Daniel Delorme, Daniel Dub e, Yves Ducharme, Erich L. Grimm, Richard Friesen, Carole Lepine